Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Common Share

Net Loss per Common Share

6 Months Ended

Jun. 30, 2021

14. Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period.

The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the three months ended June 30, 2021:



	Six Months Ended June 30,
	2021	2020
Warrants to purchase Common Stock	4,522,654	2,784,037
Options to purchase Common Stock	828,490	1,210,502
Unvested Restricted Stock	16,389,156	14,306,355
Unvested Restricted Stock Units	215,684	458,658
Total	21,955,984	18,759,552